Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.
Machine learning was used to develop a model incorporating multiple biomarkers that improved the classification of familial hypercholesterolemia.
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
A team of researchers investigated the longitudinal association between high HDL-C levels, HDL-C variability, and the risk of developing Parkinson disease.
Patients with type 2 diabetes still have a high risk for cardiovascular disease—even after lowering LDL cholesterol.
Patients with stable chest pain had four distinct patterns of metabolic phenotypes which had unique coronary artery disease trajectories and major adverse cardiovascular event risk profiles.
What do the new guidelines and recommendations advise regarding patient selection and the most appropriate clinical use of CAC scoring for ASCVD risk assessment?
The presence of cardiovascular risk factors and subclinical carotid atherosclerosis in midlife may be associated with brain hypometabolism.
Autopsy studies have shown that aortic and coronary artery atherosclerotic lesions are present in toddlers and progresses into adulthood. This study explores the development of coronary atherosclerosis due to non–HDL-C over three stages of life.
A team of researchers conducted a systematic review to examine the association between migraine and lipid profile differences.